La vendita allo scoperto per BiomX dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di BiomX. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

BiomX (AMEX:PHGE) Azioni, Report sulle vendite allo scoperto

BIOMX INC

BiomX

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

BiomX Inc

BiomX Inc Warrants (13/12/2023)

Teddy Pornprinya, co-founder and Chief Business Officer of Plume Network, believes the most immediate future of tokenized real-world assets (RWAs) lies in traditional financial instruments like treasuries and private credit—while more exotic or illiquid assets may be overhyped or too early for mass adoption.
"Top of the funnel is something super liquid and super safe," Pornprinya said in an interview with Benzinga. "So a lot of people go to different products that are like treasury-type based. Apollo's private credit fund is also a pretty safe asset that there&#8217;s been a lot of demand for."
Plume, a Layer 1 blockchain purpose-built for RWAs, has become a key infrastructure player in the space by combining tokenization with DeFi tooling, what the team calls "RWA-Fi." 
The platform allows users to buy tokenized assets, collateralize them in lending protocols, or swap them in automated market makers (AMMs), enhancing their utility far beyond passive ownership.
"We're making a lot more liquidity and utility available to what used to be static assets," he said. "The idea is that people can park their money into our RWAs, make real yield, maybe get some Plume incentives on top, and when they're done, go back into the broader DeFi ecosystem."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44672506/blackrock-ceo-larry-fink-warns-many-already-believe-the-us-is-in-a-recession">BlackRock CEO Larry Fink Warns &#8216;Many Already Believe The US Is In A Recession&#8217;</a>
<h3 class="wp-block-heading">Overhyped: Real Estate And Illiquid Exotic Assets</h3>
While there&#8217;s no shortage of excitement around tokenizing everything from diamonds to camels, Pornprinya cautioned that some assets are better left off-chain for now.
"There's this misconception where if you tokenize everything in the world, it's actually better on-chain. But some assets are better off in the real world," he said.
Citing an example, he said people think if real estate is brought on-chain there's more liquidity, but the truth is, if you&#8217;re dealing with LPs who want quicker exits, long lock-up real estate isn&#8217;t the best fit for a crypto-native environment.
<h3 class="wp-block-heading">Infrastructure And Distribution Are The Bottlenecks</h3>
Pornprinya also emphasized that tokenization isn't just about turning an asset into an on-chain wrapper. 
It's about ecosystem enablement, compliance, and access to end users. 
Plume is using a "modular compliance architecture" that supports KYC, AML, and regional licensing by integrating with partners, allowing projects to scale without being bogged down by regulatory overhead.
"Some huge asset managers we've spoken to are ready to come on-chain, but their biggest issue is distribution," he said. "How do you get more people to buy your product? That's where Plume comes in. All of our resources are dedicated to building and distributing RWA products globally."
The platform currently hosts over 200 projects ranging from tokenized solar farms and GPUs to more unconventional assets. 
But Pornprinya reiterated that user trust and asset quality are paramount. "We want to bring on quality assets that users want to use. These assets have to meet a certain criteria to flow through the RWA-Fi ecosystem."
<h3 class="wp-block-heading">Plume Eyes A Global RWA Marketplace</h3>
With institutional support from Apollo and Binance Labs, Plume is eyeing rapid global expansion. 
The platform is forming partnerships in Asia, Latin America, Africa, and the UAE. 
Looking ahead, the company is preparing for its mainnet launch in Q2 2025 and building cross-chain infrastructure in partnership with LayerZero through a new protocol called Skylink, which will allow RWA yields to stream across ecosystems like Solana.
Asked about Plume's broader vision, Pornprinya summed it up simply: "We want to be the hub for everything RWA-related. And when people ask what the ideal RWA marketplace looks like—it's Plume."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44670129/bitcoin-whipsaws-as-trillions-in-market-value-are-erased-on-fake-tariff-pause-rumor">Bitcoin Whipsaws As Trillions In Market Value Are Erased On Fake Tariff Pause Rumor</a></li>
</ul>
Image courtesy of the interviewee.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Treasuries And Private Credit Will Lead The Tokenization Wave, Says Plume Co-Founder Teddy Pornprinya

WIIM

ODFL

Old Dominion Freight Line shares are trading higher after Citigroup upgraded the stock from Neutral to Buy.

Schlumberger shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight.

Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan&nbsp;

Biotech

General

Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran For Myotonic Dystrophy Type 1

Piper Sandler analyst Kashy Harrison initiates coverage on MYR Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYRG#NASDAQ">MYRG</a>) with a Neutral rating and announces Price Target of $124.

Price Target

Initiation

Analyst Ratings

MYRG

Piper Sandler Initiates Coverage On MYR Group with Neutral Rating, Announces Price Target of $124

Weyerhaeuser shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a price target of $31.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan analyst Jeremy Tonet downgraded the rating for Dominion Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) from Neutral to Underweight and lowered the price target from $59 to $52. Dominion Energy shares closed at $50.83 on Monday. <a href="https://www.benzinga.com/quote/D/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Christine Cho downgraded Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Overweight to Equal-Weight and lowered the price target from $9 to $5. Fluence Energy shares closed at $4.29 on Monday. <a href="https://www.benzinga.com/quote/FLNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Ike Boruchow downgraded the rating for Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) from Overweight to Equal-Weight and slashed the price target from $80 to $70. Signet Jewelers shares closed at $54.64 on Monday. <a href="https://www.benzinga.com/quote/SIG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Lawson Winder downgraded Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) from Buy to Underperform and lowered the price target from $58 to $26. Alcoa shares closed at $24.59 on Monday. <a href="https://www.benzinga.com/quote/AA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Jimmy Bhullar downgraded the rating for American International Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) from Overweight to Neutral but raised the price target from $83 to $91. American International shares closed at $77.56 on Monday.  <a href="https://www.benzinga.com/quote/AIG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SIG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08085950/image-38-1024x595.png" alt="" class="wp-image-861913" style="width:526px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08085950/image-38-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08085950/image-38-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08085950/image-38-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08085950/image-38.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678688/dow-falls-for-3rd-session-amid-trumps-tariff-threats-as-apple-tesla-decline-greed-index-remains-in-extreme-fear-zone">Dow Falls For 3rd Session Amid Trump&#8217;s Tariff Threats As Apple, Tesla Decline: Greed Index Remains In &#8216;Extreme Fear&#8217; Zone</a></li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

FLNC

This Signet Jewelers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

AMZN

Amazon Unveils Amazon Nova Sonic Gen AI Model For Building Voice Applications And Agents

Macro Economic Events

Econ #s

Economics

President Trump Scheduled To Sign Energy Related Orders At The White House At 3PM April 8, 2025

CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.75, a high estimate of $23.00, and a low estimate of $18.00. This current average has increased by 2.47% from the previous average price target of $20.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1744117282_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive CVRx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;William Plovanic &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $18.00&#x7C;$23.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $20.00&#x7C;$16.00 &#x7C; 
&#x7C;William Plovanic &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $23.00&#x7C;$22.00 &#x7C; 
&#x7C;Alexander Nowak &#x7C;Craig-Hallum &#x7C;Raises &#x7C;Buy &#x7C; $22.00&#x7C;$20.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVRx. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of CVRx compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CVRx's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of CVRx's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CVRx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About CVRx</h2>
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
<h3>Unraveling the Financial Story of CVRx</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining CVRx's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 35.71% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CVRx's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -69.42%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CVRx's ROE excels beyond industry benchmarks, reaching -15.64%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): CVRx's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -8.16%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.71, CVRx adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVRX

Assessing CVRx: Insights From 4 Financial Analysts

2024: Reset. Refocus. Relaunch&nbsp;
This past year was all about setting the foundation. Here's what we have accomplished:
<ul>
<li>We went all-in on tobacco. Divested out of hemp, hops, or cannabis.</li>
<li>Streamlined our operations, diminished significant cash burn.</li>
<li>Slashed ~$18M in debt, strengthening our balance sheet&nbsp;</li>
<li>Gave VLN&#xAE; a bold new look and feel with a robust go to market strategy.</li>
<li>Developed retail partnerships that'll relaunch VLN&#xAE; in thousands of stores across the U.S. &nbsp;</li>
</ul>
Vertical Integration, Strategic Expansion
Our core contract manufacturing (CMO) business is the backbone of our operations. It's high-volume, low-margin—and absolutely essential to our success. We provide full turnkey services to secondary and tertiary tobacco brands providing manufacturing, compliance, and supply chain. They handle the brand. We handle everything else for them.
Here's why CMO is a major strategic win:
<ul>
<li>It gives us a vertically integrated platform for our core product—we control the manufacturing, distribution, and marketing of VLN&#xAE; and other proprietary products.</li>
<li>With new long-term, properly priced contracts, CMO provides revenue that addresses all of our overhead and provides stability to our operations.</li>
<li>It opens doors. We're leveraging customer partnerships and brand equity to launch VLN&#xAE; and new partner brands—growing into new channels and stores. &nbsp;</li>
</ul>
Starting Q2 2025, we're hitting the market with our bold new branding, featuring:
<ul>
<li>VLN&#xAE; Gold</li>
<li>VLN&#xAE; Red</li>
<li>VLN&#xAE; Green (Menthol) &nbsp;</li>
</ul>
Already in 5,000+ stores—and aiming for a growing slice of the 272,000-stores nationwide.
We're also launching partner-branded VLN&#xAE; products—a win-win. Our CMO customers get a premium, high-margin SKU and we get a fast track into new stores, new audiences, and greater awareness. Think of it like your favorite beverage offering a low-proof version: same vibe, less buzz, new category.
And that's exactly where we're headed: building the Very Low Nicotine Content (VLNC) category. Just like low-proof spirits carved out their space, VLN&#xAE; will stand on its own shelf—with its own story.
2025 and Beyond: Time to Grow
We've stabilized. We've streamlined. And we've struck the match and created the spark.
This year is about scale—and profit. VLN&#xAE; is our statement. Our CMO business is funding our freedom. We've got the strategy, team, and partnerships to finally take 22nd Century into self-sustaining territory.
We're not just building a brand. We're creating a whole new lane in the $85 Billion Dollar industry—and bringing smokers options with VLN&#xAE;.

XXII

22nd Century Group Announces Plans To Enter Profitable Growth Phase In 2025 With Expanded VLN Cigarette Line, Featuring New Gold, Red, And Green Variants, Leveraging Vertical Integration And Strategic CMO Partnerships To Scale Operations

Across the recent three months, 4 analysts have shared their insights on Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.25, a high estimate of $15.00, and a low estimate of $13.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 7.35%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744117272_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Nu Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Domingos Falavina &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $13.00&#x7C;$14.00 &#x7C; 
&#x7C;John Coffey &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $15.00&#x7C;$17.00 &#x7C; 
&#x7C;Domingos Falavina &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $14.00&#x7C;$15.00 &#x7C; 
&#x7C;Thiago Batista &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $15.00&#x7C;$15.50 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nu Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Nu Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Nu Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Nu Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nu Holdings analyst ratings.</a>
<h2>About Nu Holdings</h2>
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Accounts, and Rewards. The company earns the majority of its revenue in Brazil.
<h3>Nu Holdings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Nu Holdings's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 0.65%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Nu Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 26.19%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Nu Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Nu Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.12%, the company showcases efficient use of assets and strong financial health.
Debt Management: Nu Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Nu Holdings Stock

Piper Sandler analyst Kashy Harrison initiates coverage on Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Overweight rating and announces Price Target of $286.

Piper Sandler Initiates Coverage On Quanta Services with Overweight Rating, Announces Price Target of $286

RenaissanceRe Holdings shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight.

Contracts

ASNS

Actelis Networks Receives Order For Orange County's Traffic Infrastructure

Ratings for MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $165.67, a high estimate of $195.00, and a low estimate of $134.00. This upward trend is evident, with the current average reflecting a 2.9% increase from the previous average price target of $161.00.
<img src="https://www.benzinga.com/files/images/story/2025/1744117245_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of MasTec's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Kashy Harrison &#x7C;Piper Sandler &#x7C;Announces &#x7C;Overweight &#x7C; $134.00&#x7C;- &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $195.00&#x7C;$195.00 &#x7C; 
&#x7C;Alex Rygiel &#x7C;B. Riley Securities &#x7C;Raises &#x7C;Buy &#x7C; $165.00&#x7C;$151.00 &#x7C; 
&#x7C;Adam Seiden &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $145.00&#x7C;$130.00 &#x7C; 
&#x7C;Brian Brophy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $175.00&#x7C;$185.00 &#x7C; 
&#x7C;Andrew Kaplowitz &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $167.00&#x7C;$156.00 &#x7C; 
&#x7C;Andrew Wittmann &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $153.00&#x7C;$162.00 &#x7C; 
&#x7C;Drew Chamberlain &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $172.00&#x7C;$154.00 &#x7C; 
&#x7C;Brian Brophy &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $185.00&#x7C;$155.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to MasTec. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MasTec compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for MasTec's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MasTec's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MTZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MasTec analyst ratings.</a>
<h2>Discovering MasTec: A Closer Look</h2>
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.
<h3>MasTec's Economic Impact: An Analysis</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining MasTec's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.75% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: MasTec's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.2%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): MasTec's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.61%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): MasTec's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.84%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: MasTec's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.9, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 9 Analyst Projections For MasTec

Across the recent three months, 6 analysts have shared their insights on NewAmsterdam Pharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $52.00 and a low estimate of $40.00. Observing a 0.39% increase, the current average has risen from the previous average price target of $43.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1744117235_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive NewAmsterdam Pharma Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $42.00&#x7C;$42.00 &#x7C; 
&#x7C;George Farmer &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $52.00&#x7C;$47.00 &#x7C; 
&#x7C;Serge Belanger &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $42.00&#x7C;$46.00 &#x7C; 
&#x7C;Brian Abrahams &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Leonid Timashev &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $40.00&#x7C;$40.00 &#x7C; 
&#x7C;Ed Arce &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $48.00&#x7C;$48.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NewAmsterdam Pharma Co. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NewAmsterdam Pharma Co compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for NewAmsterdam Pharma Co's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NewAmsterdam Pharma Co's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NAMS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NewAmsterdam Pharma Co analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About NewAmsterdam Pharma Co</h2>
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
<h3>Key Indicators: NewAmsterdam Pharma Co's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining NewAmsterdam Pharma Co's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1490.54% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: NewAmsterdam Pharma Co's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -721.71%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): NewAmsterdam Pharma Co's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -16.22%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): NewAmsterdam Pharma Co's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -14.14%, the company may face hurdles in achieving optimal financial performance.
Debt Management: NewAmsterdam Pharma Co's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NAMS

The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts

S&amp;P Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) short percent of float has fallen 12.71% since its last report. The company recently reported that it has 3.16 million shares sold short, which is 1.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>S&amp;P Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744117232_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for S&amp;P Global has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing S&amp;P Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, S&amp;P Global's peer group average for short interest as a percentage of float is 3.54%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SPGI

Is the Market Bullish or Bearish on S&P Global?

Throughout the last three months, 5 analysts have evaluated TScan Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRX#NASDAQ">TCRX</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $9.2, along with a high estimate of $15.00 and a low estimate of $3.00. Observing a downward trend, the current average is 24.9% lower than the prior average price target of $12.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1744117227_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive TScan Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Gil Blum &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $9.00&#x7C;$9.00 &#x7C; 
&#x7C;Maxwell Skor &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Overweight &#x7C; $10.00&#x7C;- &#x7C; 
&#x7C;Peter Lawson &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $3.00&#x7C;$14.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $15.00&#x7C;$15.00 &#x7C; 
&#x7C;Gil Blum &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $9.00&#x7C;$11.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to TScan Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of TScan Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of TScan Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of TScan Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TCRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on TScan Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind TScan Therapeutics</h2>
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
<h3>TScan Therapeutics's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining TScan Therapeutics's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -90.78% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: TScan Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -5384.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): TScan Therapeutics's ROE excels beyond industry benchmarks, reaching -15.24%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): TScan Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -9.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.4.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TCRX

Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts

Conagra Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) short percent of float has risen 14.81% since its last report. The company recently reported that it has 19.76 million shares sold short, which is 4.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.24 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Conagra Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744117226_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Conagra Brands has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Conagra Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Conagra Brands's peer group average for short interest as a percentage of float is 6.10%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Conagra Brands?

Press Releases

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

BiomX Announces a Mandatory Unit Separation

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Earnings

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

Financing

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Comments

BiomX

Vendite allo scoperto

BiomX (AMEX:PHGE) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO